Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
ENTX
$1.58
$
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Beta
1.836
Average Volume
Market Cap
Last Dividend
CIK
0001638097
ISIN
IL0011429839
CUSIP
M40527109
CEO
Miranda J. Toledano
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
18
IPO Date
2018-06-28
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| What Pushed Entera Bio (ENTX) To Rally Nearly 16% After Hours | Entera Bio Ltd. shares jumped 15.71% in after-hours trading following a director's purchase of additional shares. | Benzinga | 2026-02-19 01:49:27 |
| Entera Bio Announces Open Market Purchases of Company Stock by Board Members | TEL AVIV, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that several members of its Board of Directors, including the Company's Chairman, have made open market purchases of the Company's ordinary shares. These transactions follow an earlier open market purchase by Entera Bio's Chief Executive Officer, Miranda Toledano, in December 2025. | GlobeNewsWire | 2026-02-11 09:00:00 |
| Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones | New Chairman Joins Entera's Board with Senior Global Leadership Experience from Pfizer, Wyeth and Other Leading Biopharma Companies as Entera Advances Multiple Oral Peptide Programs Toward Significant Milestones in 2026 New Chairman Joins Entera's Board with Senior Global Leadership Experience from Pfizer, Wyeth and Other Leading Biopharma Companies as Entera Advances Multiple Oral Peptide Programs Toward Significant Milestones in 2026 | GlobeNewsWire | 2026-02-09 08:50:00 |
| OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism | This is the third program that successfully combines Entera's oral peptide N-Tab® platform with OPKO's advanced protein chemistry capabilities | GlobeNewsWire | 2026-02-04 08:00:00 |
| Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook | Final EB613 Phase 3 Protocol Submission to FDA Planned for Q1 2026, Following December 19th 2025 FDA Ruling Next-Generation EB613 Phase 1 Bridging Study Progressing with Results Expected During Q1 2026 Oral Hypoparathyroidism Tablet Program to Accelerate with Lead Long-Acting PTH Variants Strategic Partnership Discussions Advancing Across Pipeline JERUSALEM, Jan. | Globe News Wire | 2026-01-21 08:30:00 |
| Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA's Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation | FDA qualification of Total Hip BMD as a validated surrogate endpoint for novel osteoporosis drug development further bolsters Entera's July 2025 FDA alignment and regulatory strategy for EB613 | GlobeNewsWire | 2025-12-23 08:30:00 |
| Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program) | Novel PTH analog achieves sustained calcium elevation for >3 days from single oral tablet, supporting development path toward once-daily alternative to daily injections Novel PTH analog achieves sustained calcium elevation for >3 days from single oral tablet, supporting development path toward once-daily alternative to daily injections | GlobeNewsWire | 2025-12-22 08:30:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-02-17 | 2026-02-17 | View Filing |
| 4 | 2026-02-11 | 2026-02-11 | View Filing |
| 4 | 2026-02-11 | 2026-02-11 | View Filing |
| 4 | 2026-02-11 | 2026-02-11 | View Filing |
| 4 | 2026-02-11 | 2026-02-11 | View Filing |
| 3 | 2026-02-09 | 2026-02-09 | View Filing |
| 8-K | 2026-02-09 | 2026-02-09 | View Filing |
| 3 | 2026-02-05 | 2026-02-05 | View Filing |
| 8-K | 2026-02-04 | 2026-02-04 | View Filing |
| 4 | 2026-01-02 | 2026-01-02 | View Filing |
| 4 | 2026-01-02 | 2026-01-02 | View Filing |
| 4 | 2026-01-02 | 2026-01-02 | View Filing |
| 4 | 2026-01-02 | 2026-01-02 | View Filing |
| 4 | 2026-01-02 | 2026-01-02 | View Filing |
| 4 | 2025-12-30 | 2025-12-30 | View Filing |
| 10-Q | 2025-11-14 | 2025-11-14 | View Filing |
| 8-K | 2025-11-14 | 2025-11-14 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| 10-Q | 2025-08-08 | 2025-08-08 | View Filing |
| 8-K | 2025-08-08 | 2025-08-08 | View Filing |
| 8-K | 2025-07-28 | 2025-07-28 | View Filing |
| 4 | 2025-07-18 | 2025-07-18 | View Filing |
| 4 | 2025-07-18 | 2025-07-18 | View Filing |
| 4 | 2025-07-18 | 2025-07-18 | View Filing |
| 8-K | 2025-07-18 | 2025-07-18 | View Filing |
| EFFECT | 2025-06-09 | 2025-06-09 | View Filing |
| 424B3 | 2025-06-06 | 2025-06-06 | View Filing |
| DEFA14A | 2025-06-05 | 2025-06-05 | View Filing |
| ARS | 2025-06-05 | 2025-06-05 | View Filing |
| DEF 14A | 2025-06-05 | 2025-06-05 | View Filing |
| S-8 | 2025-05-30 | 2025-05-30 | View Filing |
| S-3 | 2025-05-30 | 2025-05-30 | View Filing |
| 3 | 2025-05-20 | 2025-05-20 | View Filing |
| PRE 14A | 2025-05-14 | 2025-05-14 | View Filing |
| 10-Q | 2025-05-09 | 2025-05-09 | View Filing |
| 8-K | 2025-05-09 | 2025-05-09 | View Filing |
| 4 | 2025-04-30 | 2025-04-30 | View Filing |
| 4 | 2025-04-03 | 2025-04-03 | View Filing |
| SC 13G | 2025-04-02 | 2025-04-02 | View Filing |
| 10-K | 2025-03-28 | 2025-03-28 | View Filing |
| 8-K | 2025-03-28 | 2025-03-28 | View Filing |
| 8-K | 2025-03-17 | 2025-03-17 | View Filing |
| 4 | 2025-01-17 | 2025-01-17 | View Filing |
| 4 | 2025-01-17 | 2025-01-17 | View Filing |
| 4 | 2025-01-17 | 2025-01-17 | View Filing |
| 4 | 2025-01-17 | 2025-01-17 | View Filing |
| 4 | 2025-01-17 | 2025-01-17 | View Filing |
| 8-K | 2025-01-10 | 2025-01-10 | View Filing |
| 424B5 | 2025-01-10 | 2025-01-10 | View Filing |
| SC 13G | 2025-01-06 | 2025-01-06 | View Filing |
| 8-K/A | 2024-12-20 | 2024-12-20 | View Filing |
| 3 | 2024-11-20 | 2024-11-20 | View Filing |
| SC 13G/A | 2024-11-20 | 2024-11-20 | View Filing |
| 10-Q | 2024-11-08 | 2024-11-08 | View Filing |
| 8-K | 2024-11-08 | 2024-11-08 | View Filing |
| 4 | 2024-10-04 | 2024-10-04 | View Filing |
| 4 | 2024-10-04 | 2024-10-04 | View Filing |
| 4 | 2024-10-04 | 2024-10-04 | View Filing |
| 4 | 2024-10-04 | 2024-10-04 | View Filing |
| 4 | 2024-10-04 | 2024-10-04 | View Filing |
| 4 | 2024-08-29 | 2024-08-29 | View Filing |
| 4 | 2024-08-29 | 2024-08-29 | View Filing |
| 4 | 2024-08-29 | 2024-08-29 | View Filing |
| 4 | 2024-08-29 | 2024-08-29 | View Filing |
| 4 | 2024-08-29 | 2024-08-29 | View Filing |
| SC 13G/A | 2024-08-20 | 2024-08-20 | View Filing |
| S-8 | 2024-08-09 | 2024-08-09 | View Filing |
| 10-Q | 2024-08-09 | 2024-08-09 | View Filing |
| 8-K | 2024-08-09 | 2024-08-09 | View Filing |
| 8-K | 2024-08-02 | 2024-08-02 | View Filing |
| 4/A | 2024-08-02 | 2024-08-02 | View Filing |
| 4 | 2024-08-02 | 2024-08-02 | View Filing |
| DEFA14A | 2024-06-20 | 2024-06-20 | View Filing |
| ARS | 2024-06-20 | 2024-06-20 | View Filing |
| DEF 14A | 2024-06-20 | 2024-06-20 | View Filing |
| 3 | 2024-06-07 | 2024-06-07 | View Filing |
| PRE 14A | 2024-05-29 | 2024-05-29 | View Filing |
| 10-Q | 2024-05-10 | 2024-05-10 | View Filing |
| 8-K | 2024-05-10 | 2024-05-10 | View Filing |
| 4 | 2024-04-23 | 2024-04-23 | View Filing |
| 4 | 2024-04-23 | 2024-04-23 | View Filing |
| S-8 | 2024-03-08 | 2024-03-08 | View Filing |
| 10-K | 2024-03-08 | 2024-03-08 | View Filing |
| 8-K | 2024-03-08 | 2024-03-08 | View Filing |
| 8-K | 2024-03-04 | 2024-03-04 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Williams PercentR Strategy | 48.39% | 1 | 292 | 0.04 | 0.08 | 56.94 |
| Larry Williams PercentR Strategy | 29.49% | 1.01 | 161 | 0.03 | 0.07 | 38.04 |
| Keltner Channel Strategy | 24.76% | 1.03 | 106 | 0.02 | 0.05 | 33.32 |
| xxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | x | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxx | x% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |